Copy to clipboard 
Tenon Medical announced completion of the first clinical procedures utilizing the company’s new SImmetry+ SI Joint Fusion System. The company acquired sacroiliac (SI) joint-specific assets from SiVantage earlier this year.
Symmetry+ is a next-generation, minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles, including joint decortication, bone graft placement, and rigid fixation, with the goal of achieving a true biological fusion across the SI joint. The system features 3D-printed titanium implants engineered to effectively stabilize the SI Joint by incorporating a self-drilling, self-tapping, and self-harvesting design, which streamlines implantation and enhances bone preparation and fusion. The system is cleared for use with one to three implants.
Initial physician use of SImmetry+ is underway through a controlled, early-access rollout with a select group of experienced SI fusion physicians. These early adopters will provide important procedural and clinical feedback on the implant design, technique, and instrumentation to support a broader commercial launch readiness. Additional alpha cases are currently being scheduled at multiple Centers of Excellence across the United States.
Clinical evidence supporting the SImmetry+ system includes 12-month outcomes from the EvoluSIon study. Among 250 treated patients, the procedure demonstrated a strong safety profile, resulting in meaningful reductions in pain and improvements in quality-of-life measures. Patients also experienced a 57.1% decrease in pre-operative opioid use and at 12 months, 68.7% of patients showed radiographic fusion of the SI joint confirmed by computed tomography and independently reviewed by a trained radiologist.
“The first successful clinical use of SImmetry+ represents another meaningful milestone in Tenon’s mission to advance sacro-pelvic fusion options for physicians and their SI joint patients,” said Steve Foster, President and Chief Executive Officer of Tenon Medical. “Ongoing feedback from our physician advisors guides us in refining every aspect of the system and workflow. These technologies only reach their full potential with world-class clinical insight, and we are deeply grateful for the expertise our advisors bring. SImmetry+ combines proven orthopedic fusion principles with modern implant and instrument design to support a true fusion approach. Early clinical feedback reinforces our belief that this next-generation technology can further accelerate adoption and strengthen our growing sacro-pelvic portfolio.”
Source: Tenon Medical, Inc.
Tenon Medical announced completion of the first clinical procedures utilizing the company's new SImmetry+ SI Joint Fusion System. The company acquired sacroiliac (SI) joint-specific assets from SiVantage earlier this year.
Symmetry+ is a next-generation, minimally invasive lateral access solution that incorporates well-established...
Tenon Medical announced completion of the first clinical procedures utilizing the company’s new SImmetry+ SI Joint Fusion System. The company acquired sacroiliac (SI) joint-specific assets from SiVantage earlier this year.
Symmetry+ is a next-generation, minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles, including joint decortication, bone graft placement, and rigid fixation, with the goal of achieving a true biological fusion across the SI joint. The system features 3D-printed titanium implants engineered to effectively stabilize the SI Joint by incorporating a self-drilling, self-tapping, and self-harvesting design, which streamlines implantation and enhances bone preparation and fusion. The system is cleared for use with one to three implants.
Initial physician use of SImmetry+ is underway through a controlled, early-access rollout with a select group of experienced SI fusion physicians. These early adopters will provide important procedural and clinical feedback on the implant design, technique, and instrumentation to support a broader commercial launch readiness. Additional alpha cases are currently being scheduled at multiple Centers of Excellence across the United States.
Clinical evidence supporting the SImmetry+ system includes 12-month outcomes from the EvoluSIon study. Among 250 treated patients, the procedure demonstrated a strong safety profile, resulting in meaningful reductions in pain and improvements in quality-of-life measures. Patients also experienced a 57.1% decrease in pre-operative opioid use and at 12 months, 68.7% of patients showed radiographic fusion of the SI joint confirmed by computed tomography and independently reviewed by a trained radiologist.
“The first successful clinical use of SImmetry+ represents another meaningful milestone in Tenon’s mission to advance sacro-pelvic fusion options for physicians and their SI joint patients,” said Steve Foster, President and Chief Executive Officer of Tenon Medical. “Ongoing feedback from our physician advisors guides us in refining every aspect of the system and workflow. These technologies only reach their full potential with world-class clinical insight, and we are deeply grateful for the expertise our advisors bring. SImmetry+ combines proven orthopedic fusion principles with modern implant and instrument design to support a true fusion approach. Early clinical feedback reinforces our belief that this next-generation technology can further accelerate adoption and strengthen our growing sacro-pelvic portfolio.”
Source: Tenon Medical, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
